1. Cancer Biology
  2. Medicine

A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis

  1. Ming Chao
  2. Hao Wu
  3. Kai Jin
  4. Bin Li
  5. Jianjun Wu
  6. Guangqiang Zhang
  7. Gong Yang
  8. Xun Hu  Is a corresponding author
  1. The Second Affiliated Hospital of Zhejiang University School of Medicine, China
  2. Vanderbilt University Medical Center, United States
https://doi.org/10.7554/eLife.15691
Share this article
Cite this article
  1. Ming Chao
  2. Hao Wu
  3. Kai Jin
  4. Bin Li
  5. Jianjun Wu
  6. Guangqiang Zhang
  7. Gong Yang
  8. Xun Hu
(2016)
A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
eLife 5:e15691.
https://doi.org/10.7554/eLife.15691
  2. Download BibTeX
  3. Download .RIS

Abstract

Background: Previous works suggested that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor. We did a pilot clinical investigation, including a nonrandomized (57 patients with large HCC) and a randomized controlled (20 patients with large HCC) study.

Methods: The patients were treated with transarterial chemoembolization (TACE) with or without bicarbonate local infusion into tumor.

Results: In the nonrandomized controlled study, geometric mean of viable tumor residues (VTR) in TACE with bicarbonate was 6.4-fold lower than that in TACE without bicarbonate (7.1% [95% CI: 4.6%–10.9%] vs 45.6% [28.9%–72.0%]; p<0.0001). This difference was recapitulated by a subsequent randomized controlled study. TACE combined with bicarbonate yielded a 100% objective response rate (ORR), whereas the ORR treated with TACE alone was 44.4% (nonrandomized) and 63.6% (randomized). The survival data suggested that bicarbonate may bring survival benefit.

Conclusions: Bicarbonate markedly enhances the anticancer activity of TACE.

Funded by National Natural Science Foundation of China.

Clinical trial registration number, ChiCTR-IOR-14005319.

eLife digest

Surgery is the main treatment for liver cancer, but the most common liver cancer – called hepatocellular carcinoma – can sometimes become too large to remove safely. An alternative option to kill the tumor is to block its blood supply via a process called embolization. This procedure deprives the tumor cells of oxygen and nutrients such as glucose. However, embolization also prevents a chemical called lactic acid – which is commonly found around tumors – from being removed. Lactic acid actually helps to protect cancer cells and also aids the growth of new blood vessels, and so the “trapped” lactic acid may reduce the anticancer activity of embolization.

Previous works suggested that neutralizing the acidic environment in a tumor while depriving it of glucose via embolization could become a new treatment option for cancer patients. Chao et al. now report a small clinical trial that tested this idea and involved patients with large hepatocellular carcinomas. First, a group of thirty patients received the embolization treatment together with an injection of bicarbonate – a basic compound used to neutralize the lactic acid – that was delivered directly to the tumor. The neutralization killed these large tumors more effectively than what is typically seen in patients who just undergo embolization

Chao et al. then recruited another twenty patients and randomly assigned them to receive either just the embolization or the embolization with bicarbonate treatment. This randomized trial showed that the tumors died more and patients survived for longer if they received the bicarbonate together with the embolization treatment compared to those patients that were only embolized. In fact, four patients initially assigned to, and treated in, the embolization-only group subsequently asked to cross over to, and indeed received, the bicarbonate treatment as well.

These data indicate that this bicarbonate therapy may indeed be effective for patients with large tumors that are not amenable to surgery. In future, larger clinical trials will need to be carried out to verify these initial findings.

Introduction

We recently found that Lactic acidosis could effectively protect cancer cells against glucose starvation or deprivaiton (Wu et al., 2012; Xie et al., 2014). First, lactic acidosis dramatically reduces glycolysis rate with little wasting glucose to lactate, as such, a limited amount of glucose could support cancer cells for a relatively long time otherwise would be exhausted quickly. Second, when glucose was deprived, lactic acidosis transformed cancer cells to a ‘dormant’ state, via arresting cells at G0/G1 phase, initiating autophagy, inhibiting apoptosis, etc. The protective function relies on co-presence of lactate and proton, depriving either of which would abolish the function (Wu et al., 2012; Xie et al., 2014). When converting lactic acidosis to lactosis by a base, the protective function is gone; similarly, removing lactate, acidosis conferred cancer cells with little resistance to glucose deprivation.

The significance of intratumoral lactic acidosis in tumor biology has been extensively revealed by many other investigators. Clinical studies showed that high level of lactate was a strong prognostic indicator of increased metastasis and poor overall survival (Gatenby and Gillies, 2004; Brizel et al., 2001; Walenta et al., 2000; Schwickert et al., 1995; Walenta et al., 1997; Yokota et al., 2007; Paschen et al., 1987). The work of Gillies and Gatenby group demonstrated that systematic and tumor pHe alkalization could inhibit carcinogenesis, tumor invasion and metastasis, and they also provided integrated models that can predict the safety and efficacy of buffer therapy to raise tumour pHe (Silva et al., 2009; Robey et al., 2009; Ibrahim-Hashim et al., 2012) and related theoretical work (Martin et al., 2012, Martin et al., 2011). Furthermore, many studies reported that lactic acidosis played multifaceted roles in skewing macrophages (Colegio et al., 2014) and inhibiting the function of cytotoxic T cells (Haas et al., 2015), altering cancer cell metabolism (Chen et al., 2008; Sonveaux et al., 2008), inducing chromosomal instability (Dai et al., 2013), and promoting tumor angiogenesis (Gatenby and Gillies, 2004; Végran et al., 2011).

According to the guideline of Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy, HCC larger than 3 cm in diameter is not suitable for curative therapy (surgical resection, liver transplantation, and ablation) and the recommended treatment is TACE (Forner et al., 2012; El-Serag, 2011; Knox et al., 2015). But sadly, it is recognized that TACE is not effective to treat large tumors (Sieghart et al., 2015). This leaves the patients with large HCC without choice of effective therapy, as also pointed out by Sieghart et al, “maximal restriction of patients selection for TACE would otherwise only improve the results of the treatment modality per se but again would leave those more advanced patients within the intermediate stage without treatment options.” (Sieghart et al., 2015)

TACE is for local control of the targeted tumor. TEX equation checkTACE kills HCC via 2 mechanisms, delivering concentrated anticancer drugs locally into tumor and occluding tumor feeding arteries to deprive nutrients to starve cancer cells. We would focus on the second mechanism. Occluding tumor feeding arteries effectively deprive nutrients including glucose. The problem is that embolization-created hypoxia condition would stimulate cancer cells to emit strong signals to initiate angiogenesis (Knox et al., 2015) to reestablish tumor vasculature to bypass the occluded tumor feeding arteries. If the tumor cells cannot be rapidly eliminated, tumor vasculature would be re-established, and a certain amount of tumor (ranging from a few percent of the original tumor to even a larger tumor known as progressive disease) would survive and thrive. The lactate concentrations in HCC biopsies were around 20 mM (unpublished data), suggesting a lactic acidosis condition. After TACE, lactic acidosis would be trapped in embolized tumor and it would potentially attenuate the therapeutic efficacy of TACE. If it were true, locally infusion of bicarbonate to neutralize it would result in a severer necrosis in the embolized area.

Results

Local control of targeted large tumors as assessed by viable tumor residues (VTR)

TACE is to control the targeted tumors rather than to systematically control the disease. As such, to measure the necrosis of the targeted tumors can quantitatively reflect the therapeutic efficacy of TACE. It is known that large size of HCC is a major obstacle to limit the therapeutic efficacy of TACE (Sieghart et al., 2015), the larger the tumor size, the poorer the efficacy of TACE. Thus, the large HCC is a perfect tumor model to test our hypothesis. If intratumoral lactic acidosis is responsible for the therapeutic limitation, locally neutralizing it should significantly improve the anticancer activity, which can be quantitatively measured by the viable tumor residues. To the best of our knowledge, assessment of the necrosis of tumor after the first treatment is probably most objective with least interferences of known and unknown factors. Unless otherwise indicated, the data presented below are the response to the first TACE treatment.

We retrieved 27 patients with large HCC (ranging 5.0–14.6 cm) from the pool of patients treated with cTACE in the hospital between 2010 and 2012 according to the inclusion and exclusion criteria as specified in the Materials and methods section. The amount of viable tumor residues after cTACE treatment was calculated. We then recruited 30 patients for the TILA-TACE group using the same inclusion and exclusion criteria between 2012 and 2013. Most of patients’ demographic and clinicopathologic characteristics between the two treatment groups cTACE and TILA-TACE were generally comparable (Table 1). However, patients in the cTACE group were more likely to have multifocal tumors.

Table 1
Clinical and tumor characteristics of patients treated with cTACE and TILA-TACE in the nonrandomized study.
VariablesPatients
TILA-TACEcTACE
Patient number3027
Median age, years57 (Range 32–81)54 (Range 37–81)
Gender (M/F)27/3 (90.0%/10.0%)27/0 (100%/0%)
Aetiology
 HBV24 (80.0%)25 (92.6%)
 HCV0 (0%)0 (0%)
 Non B-non C6 (20.0%)2 (7.4%)
Cirrhosis (radiology)30 (100%)27 (100%)
Bilirubin, μM16.9 ± 9.422.5 ± 11.6
Albumin, g/L39.0 ± 6.937.4 ± 5.3
AST, U/L74.9 ± 102.383.5 ± 54.1
ALT, U/L54.1 ± 80.467.3 ± 43.5
AFP, >400 ng/mL9 (30.0%)15 (55.6%)
Child-Pugh class, A/B27/3 (90.0%/10.0%)25/2 (92.6%/7.4%)
The size of largest tumor (cm)9.2 (range 5.0–13.6)10.3 (range 5.0–14.6)
 Tumor >10 cm14 (46.7%)15 (55.6%)
 Tumor 5~10 cm16 (53.3%)12 (44.4%)
Multifocal tumors in 1 lobe8 (26.7%)12 (44.4%)
Multifocal tumors in 2 lobes8 (26.7%)12 (44.4%)
BCLC stage
 B19 (63.3%)18 (66.7%)
 C11 (36.7%)9 (33.3%)
Macrovascular invasion5 (16.7%)4 (14.8%)
 The right branch of portal vein4 (13.3%)2 (7.4%)
 Hepatic vein–1 (3.7%)
 The right branch of portal + hepatic vein1 (3.3%)1 (3.7%)
Extra-hepatic metastasis8 (26.7%)8 (29.6%)
 Lung1 (3.3%)6 (22.2%)
 Lung + bone1 (3.3%)0 (0%)
 Soft tissue–0 (0%)
 Lymph nodes5 (12.2%)0 (0%)
 Bone1 (2.0%)1 (3.7%)
 Bone+lymph node–1 (3.7%)

  1. HBV, hepatitis B virius;

    HCV, hepatitis C virius;

  2. AST, Aspartate transaminase;

    ALT, Alanine aminotransferase;

  3. AFP, alpha-feto-protein.

Table 2
Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the nonrandomized cohort of 57 patients.
Geometric mean (95% CI)
cTACE (n=27)TILA-TACE (n=30)p value
Crude VTR45.1% (30.3%–67.0%)7.1% (4.4%–11.5%)<0.0001
Multivariable adjusted VTR*45.6% (28.9%–72.0%)7.1% (4.6%–10.9%)<0.0001

  1. VTR: viable tumor residues;

    cTACE: transarterial chemoembolization;

  2. TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;

    *Adjusted for viable tumor volume prior to treatment and macrovascular invasion using the general linear regression. No appreciable alterations in results were found after adjustment for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, and tumor multifocality.

The geometric mean of VTR after the first treatment was 45.1% (95% CI: 30.3%–67.0%) in the cTACE group, significantly greater than that in the TILA-TACE (7.1% [95% CI: 4.4%–11.5%]; p<0.0001) (Table 2 and Figure 1). We further evaluated whether treatment effects (VTR) were confounded by some covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, viable tumor volume before treatment, macrovascular invasion, and tumor multifocality using general linear models. In this study, none of these clinical covariates were significantly associated with VTR (data not shown). Adjustment of these variables did not appreciably alter the results (Table 2). We then calculated the relative therapeutic improvement by TILA-TACE as described in Materials and methods. TILA-TACE achieved a 81.1% therapeutic improvement relative to cTACE.

Figure 1
Download asset Open asset
Viable tumor residues (VTR) after treatment of cTACE verus TILA-TACE.

Patients’ demographic parameters were described in Table 1. The relative therapeutic improvement by TILA-TACE was 81.1%. Relative therapeutic improvement by bicarbonate is defined as [(μ1-μ2)/μ1] × (100%), where μ1 is the mean of viable tumor residues after treatment (cTACE) and μ2 the mean residual after treatment (TILA-TACE), and the maximal therapeutic improvement is 100%. Differences in VTR between two groups were statistically significant (p<0.0001), as assessed using the general linear model after adjustment for viable tumor volume before treatment

Figure 1—source data 1

Calculation of viable volume residues of each patient in the nonrandomized study after the first round treatment.

https://cdn.elifesciences.org/articles/15691/elife-15691-fig1-data1-v2.xlsx

We also categorized tumor responses to treatment into four categories from complete response (CR) to progressive disease (PD) according to EASL criteria. Complete or partial responses to treatment in the TILA-TACE group were significantly higher than that in the cTACE group. The percentage of CR, PR, SD, and PD in the cTACE group was 0%, 44.4%, 33.3%, and 22.2% (Figure 2A), respectively, compared with 23%, 77%, 0%, and 0%, respectively, in the TILA-TACE group (Figure 2B). The total objective response rate (complete or partial responses) in the cTACE group was 44.4%, whereas it was 100% in the TILA-TACE group (Figure 2C). The observed greater responses to treatment in the TILA-TACE than in the cTACE persisted after accounting for tumor volume prior to treatment using the proportional odds model (p<0.0001).

Figure 2
Download asset Open asset
Tumor objective response to cTACE or TILA-TACE categorized according to EASL criteria.

Rate of tumor response to treatment and representative MRI images of tumor before and after treatment (A) in the cTACE group (n=27) and (B) in the TILA-TACE group (n=30). (C) The difference in tumor responses between two groups was statistically significant (p<0.0001), as assessed by the proportional odds model after adjustment for viable tumor volume before treatment. CR, complete necrosis; PR, viable tumor volume less than 50% of the viable tumor volume before treatment; SD, viable tumor volume larger than 50% of the viable tumor volume before treatment; PD, viable tumor volume larger than 100% after treatment.

Figure 2—source data 1

The criteria and classification of response to treatment in the nonrandomized study after the first round treatment.

https://cdn.elifesciences.org/articles/15691/elife-15691-fig2-data1-v2.xlsx

Because of the marked therapeutic improvement by TILA-TACE, the sample size required for the subsequent RCT to evaluate tumor responses to treatment was rather small. When patient number was 10 for each group, the estimated power value reached 0.826. In 2014, we recruited and randomly assigned twenty patients with large HCC (5.0 – 13.5 cm) into cTACE (n=10) or TILA-TACE (n=10). Again, most of the selected clinicopathologic characteristics were well matched between two treatment groups (Table 3). After completion of the first treatment, the VTR in the TILA-TACE group was 5.5-fold lower than that in the cTACE group (4.6% [95% CI: 1.8%–11.4%] vs. 25.4% [95% CI: 10.1%–64.0%]; p=0.008) (Figure 3 and Table 4). We also evaluated whether the treatment effect was confounded by aforementioned clinical parameters in the RCT. Among them, only viable tumor volume before treatment was significantly associated with VTR. Adjustment for tumor volume before treatment slightly changed the results, with the VTR in the TILA-TACE of 4.1% (2.0%–8.4%) vs. 28.1% (13.9%–56.8%) in the cTACE (p=0.0009). The relative therapeutic improvement by bicarbonate in the RCT was 80.1%, similar to that observed in the non-randomized cohort, 81.1%.

Table 3
VariablesPatients
TILA-TACEcTACE
Patient number1010
Median age, years58 (Range 40–86)53 (43–81)
Gender (M/F)9 /1 (90.0%/10.0%)7 /3 (70.0%/ 30.0%)
Aetiology
 HBV9 (90.0%)8 (80.0%)
 HCV0 (0%)0 (0%)
 Non B-non C1 (10.0%)2 (20.0%)
Cirrhosis (radiology)10 (100%)10 (100%)
Bilirubin, μM17.2 ± 10.116.7 ± 7.6
Albumin, g/L38.7 ± 3.138.1 ± 5.2
AST, U/L64.8 ± 44.852.8 ± 19.2
ALT, U/L60.6 ± 48.041.0 ± 29.9
AFP, >400 ng/mL3 (30.0%)4 (40.0%)
Child-Pugh class, A/B10/0 (100%/0%)10/0 (100%/0%)
The size of largest tumor (cm)7.9 (range 5.0–13.5)7.5 (range 5.0–13.0)
 Tumor >10 cm3 (30.0%)3 (30.0%)
 Tumor 5~10 cm7 (70.0%)7 (70.0%)
Multifocal tumors in 1 lobe3 (30.0%)3 (30.0%)
Multifocal tumors in 2 lobes4 (40.0%)2 (20.0%)
BCLC stage
 B7 (70.0%)8 (70.0%)
 C3 (30.0%)2 (20.0%)
Macrovascular invasion2 (20.0%)1 (10.0%)
 The right branch of portal vein1 (10.0%)1 (10.0%)
 The left branch of portal vein1 (10.0%)0 (0%)
Extra-hepatic metastasis1 (10.0%)2 (20.0%)
 Brain0 (0%)1 (10.0%)
 Lymph nodes1 (10.0%)1 (10.0%)

  1. HBV, hepatitis B virius;

    HCV, hepatitis C virius;

  2. AST, Aspartate transaminase;

    ALT, Alanine aminotransferase;

  3. AFP, alpha-feto-protein.

Figure 3
Download asset Open asset
Viable tumor residues after treatment with cTACE or TILA-TACE in the randomized controlled study.

The relative therapeutic improvement by TILA-TACE was 80.1%. Differences in VTR between two arms were statistically significant (p=0.0009), as assessed using the general linear model after adjustment for viable tumor volume before treatment.

Figure 3—source data 1

Calculation of viable volume residues of each patient in the randomized study after the first round treatment.

https://cdn.elifesciences.org/articles/15691/elife-15691-fig3-data1-v2.xlsx
Table 4
Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the RCT.
Geometric mean (95% CI)
cTACE (n=10)TILA-TACE (n=10)p value
Crude VTR25.4% (10.1%–64.0%)4.6 (1.8%–11.4%)0.008
Multivariable adjusted VTR*28.1% (13.9%–56.8%)4.1 (2.0%–8.4%)0.0009

  1. VTR: viable tumor residues;

    cTACE: transarterial chemoembolization;

  2. TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;

    RCT: randomized clinical trial.

  3. *Adjusted for viable tumor volume prior to treatment using the general linear regression. No appreciable alterations in results were found after adjusting for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, macrovascular invasion, and tumor multifocality individually.

If assessed by tumor objective response rate according to the EASL criteria, in TILA-TACE group, out of 12 targeted tumors, 4 achieved CR and 8 PR (Figure 4), whereas in cTACE group, out of 11 targeted tumors, 1 achieved CR, 6 PR, 2 SD, and 2 PD (Figure 4), with P value of 0.003 after adjustment for tumor volume prior to treatment. A similar result was found when assessing treatment effects for the largest tumor (p=0.003). In this RCT, the ORR in TILA-TACE group was 100% and the ORR in cTACE group was 63.6%.

Figure 4
Download asset Open asset
Tumor objective response to cTACE or TILA-TACE according to EASL criteria.

Twenty patients were randomly assigned to treatment of cTACE or TILA-TACE. (A) Tumor response rate to cTACE and representative MRI images of tumor before and after treatment. 10 patients were treated with cTACE. (B) Tumor response rate to TILA-TACE and representative MRI image of tumor before and after treatment. 10 patients were treated with TILA-TACE. (C) The pattern of tumor response to TILA-TACE and cTACE. The difference between 2 groups was statistically significant (p=0.003), as assessed using proportional odds model. CR, complete necrosis; PR, viable tumor volume less than 50% of the viable tumor volume before treatment; SD, viable tumor volume larger than 50% of the viable tumor volume before treatment; PD, viable tumor volume larger than 100% after treatment.

Figure 4—source data 1

The criteria and classification of response to treatment in the randomized study after the first round treatment.

https://cdn.elifesciences.org/articles/15691/elife-15691-fig4-data1-v2.xlsx

Overall survival

In the nonrandomized cohort of study, the 1-, 2-, 3-year survival of 27 patients treated with cTACE retrieved from our database were 66.7% (95% CI 45.7%–81.1%), 40.7% (95% CI 22.5%–58.2%), and 25.9% (95% CI 11.5%–43.1%), respectively, with a median survival of 14 months (Figure 5A), and the 1-, 2-, 3-year survival of 30 patients treated with TILA-TACE were 82.8% (95% CI 63.4%–92.8%), 67.7% (95% CI 47.0%–81.8%), and 61.8% (95% CI 39.7%–77.8%), respectively, with a median survival beyond 41 months (Figure 5A). The survival difference between TILA-TACE and cTACE was statistically significant (p=0.0052).

Figure 5
Download asset Open asset
Kaplan-meier analysis of cumulative survival of patients receiving TILA-TACE or cTACE treatment.

(A) Cumulative survival of patients described in Table 1. p=0.0052. (B) Survival of patients described in Table 2. Left panel, all patients; right panel, patients who initially assigned to cTACE but subsequently crossed over to TILA-TACE treatment were excluded. p>0.05. (C) Cumulative Survival of patients pooled from Table 1 and 2. p=0.0133.

Figure 5—source data 1

The survival status of each patient at the cut-off date in the nonrandomized and the randomized studies.

https://cdn.elifesciences.org/articles/15691/elife-15691-fig5-data1-v2.xlsx

In the randomized study, 4 patients initially assigned in and treated with cTACE group subsequently requested to cross over to TILA-TACE treatment. Although the cross-over was ethically warranted, this somehow blurred the overall survival difference between cTACE and TILA-TACE (Figure 5B). In cTACE group, 3 deaths occurred in 6 patients who solely received cTACE treatment, and 4 patients who initially received cTACE treatment and subsequently crossed over to TILA-TACE treatment were alive. In TILA-TACE group of 10 patients, 3 deaths occurred and 7 patients live. There was no apparent difference in overall survival between two treatment groups in the intent-to-treat (ITT) analysis (Figure 5B, left panel). However, a survival advantage appears in TILA-TACE treatment over cTACE treatment in the per-protocol (PP) analysis (Figure 5B, right panel), but statistically not significant. Overall, the RCT was limited by the small sample size and the result of the PP analysis was potentially confounded by the crossover of patients from cTACE group to TILA-TACE.

After pooling all patients together, there was a significant difference of survival between cTACE and TILA-TACE group (Figure 5C).

Adverse effects

The adverse effect between cTACE and TILA-TACE group were comparable (Tables 5 and 6).

Table 5
Adverse events of patients receiving TILA-TACE or cTACE.
Adverse events*TILA-TACEcTACE†
Pain5 out of 303 out of 27
Fever (≥38.5)‡13 out of 309 out of 27

  1. * The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.

    † Patients were retrospectively retrieved from our database.

  2. ‡ Mild fever occurred to all patients.

Table 6
Adverse events in patients in the RCT.
Adverse events*TILA-TACEcTACE
Pain2 out of 101 out of 10
Fever (≥38.5)†2 out of 103 out of 10

  1. * The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.

    † Mild fever occurred to all patients.

Discussion

In this clinical investigation, we carried out 2 studies sequentially, the first one is a nonrandomized controlled study, which demonstrated a remarkable therapeutic improvement of TILA-TACE, based on which, a randomized controlled study was designed and carried out, and again it demonstrated a superior anticancer activity of TILA-TACE. The most striking point is that the numbers reflecting the therapeutic improvements by TILA-TACE from the 2 studies were nearly identical (81.1% and 80.1%). This confirms the consistency of anticancer activities of cTACE as well as TILA-TACE with respect to local control of large HCC.

We compared the ORR in our cTACE practice with those reported globally. The average objective tumor response to TACE is 35% (range, 16%–61%), as systematically reviewed by LIovet and Bruix for the Barcelona-Clinic Liver Cancer Group in 2002 (Llovet and Bruix, 2003). In 2012, Forner, LIovet, and Bruix summarized that more than 50% of patients had an objective response to TACE (Forner et al., 2012), suggesting that the objective tumor response to TACE in the 10-year period (2002–2012) had been increased for about 15%. The complete tumor response to TACE is rare (0-4.8%) (Jansen et al., 2005). Obviously, the results obtained from our cTACE practice were similar to those reported globally.

TACE is for local control of the targeted tumor. Many previous studies have confirmed that better local control was an independent prognostic indicator for patient survival (Kim et al., 2015; Jung et al., 2013; Kim et al., 2013; Shim et al., 2012; Riaz et al., 2011; Gillmore et al., 2011; Riaz et al., 2010). Kim et al and Shim et al (Kim et al., 2015; Shim et al., 2012) further demonstrated a clear prognostic difference between CR, PR, stable disease and progressive disease. The current study demonstrated that TILA-TACE achieved a remarkable improvement of local tumor control and suggested an early sign of improved survival for patients with large HCCs (Figure 5A). It is noted that, during follow up, 16 patients in the TILA-TACE arm (Figure 5A), eventually exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis, all of which may account for the death (Supplementary file 2). These observations suggest that fast CR and timely control of recurrent tumors in the liver would likely improve the survival of patients, especially those with large tumor burden and low liver reserve.

Nevertheless, the work is limited by the study design. The randomized controlled study designed in this investigation was for local tumor control, not for survival. Although the small sample size allowed us to evaluate the local tumor control, we did not expect that such small sample size would yield statistically significant data for cumulative survival. Evaluation of survival is a matter much more complicated than evaluation of local control. There are many more factors affecting the survival of patients than those affecting the local tumor control, e.g., tumor characteristics, liver function reserve, tumor staging, disease complications, vascular invasion, metastasis, etc., all of which must be well controlled. While we acknowledged these limitations of the present small RCT, the preliminary survival data allowed us to rationally calculate the sample size for a subsequent large RCT for evaluating the survival difference between cTACE and TILA-TACE. We are planning a large-scale RCT to further confirm the therapeutic advantage of TILA-TACE with respect to overall and progression-free survival of patients with large HCCs.

There was no significant difference of adverse effect between TILA-TACE and cTACE (Tables 3 and 4), i.e., TILA-TACE was as tolerable as cATCE. It was within our expectation, as locally administration of bicarbonate into tumor is safe.

Taken together, this pilot study demonstrated that bicarbonate infusion locally into HCC can markedly enhance anticancer activity of TACE, supporting the notion that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor.

Materials and methods

Patients and study design

Request a detailed protocol

The study was performed with patients’ written informed consent and with the approval of hospital’s Institutional Review Board. Patients’ consent to publish is obtained. The study is composed of 2 parts (Reporting standard 1). In the first part, twenty seven patients treated with cTACE were retrospectively retrieved (February 2010 – March 2012) (Supplementary file 1) and the viable tumor residues were calculated, and 30 patients (January 2012 – September 2013) (Supplementary file 2) with large HCC were recruited and treated with TILA-TACE (targeting-intratumoral-lactic-acidosis TACE, in this modality, bicarbonate was infused into tumor to neutralizing intratumoral lactic acidosis). In the second part, the data generated from part 1 were used to estimate the sample size for a subsequent randomized controlled study. Twenty patients (March 2014 – August 2014) (Supplementary file 3) were randomly assigned to either TILA-TACE or cTACE treatment with ratio 1:1 (registration number: ChiCTR-IOR-14005319 in Chinense Clinical Trial Registry; protocol [Supplementary file 5] can be accessed at http://www.medresman.org/), according to the method of random number table. Patient inclusion criteria are: a diagnosis of HCC based on EASL or histological evidence, Barcelona Clinic Liver Cancer (BCLC) stage B or C, Child-pugh A or B, adult patients of age ≥ 20, hypervascular lesion as evaluated by triphasic MRI and digital subtraction angiography (DSA). Patient exclusion criteria are: BCLC stage 0, A or D, Child pugh C, evidence of combined A-V shunt.

Sample size calculation in the RCT

Request a detailed protocol

Sample size calculation was determined by the values of power and alpha: power (0.8) and alpha (0.05) can properly tell the statistical significance and minimize the number of patients to receive false choice of therapy. In order to calculate sample size for RCT, we calculate the viable tumor residues of 30 patients treated with TILA-TACE and 27 patients treated with cTACE as described below (Evaluation of tumor response, Calculation of total tumor volume, viable tumor volume, and necrotic tumor volume). Based on these data, we assessed the minimal number of patients required in a subsequent RCT. We assume the probability of making a Type I error to be 0.05 (α, two-sided), and the probability of making a Type II error to be 0.20 (β level), so the power of this RCT is 0.8 (1-β). The sample size was calculated according to Schouten’s general formula:

n1 ≥ (z1−α2+zβ)2(τ+γ)σ12γ(μ1−μ2)2+(τ2+γ3)z1−α/222γ(τ+γ)2

Where n1 and n2 represent the number of patients assigned to cTACE and TILA-TACE group, γ=n1/n2, μ1 (cTACE) and μ2 (TILA-TACE) is the mean viable tumor residues, and σ1 and σ2 are the corresponding standard deviation, τ=σ22/σ12, and Z is the normal deviate for alternative hypothesis at a level of significance. In practice, we used PASS software (version 11) to calculate the power and sample size, using the parameters mentioned above. As can been seen in Supplementary file 4, 9 patients in each group already satisfy the power and alpha value. For a pilot study, the sample size of 10 patients for each group was appropriate, as the estimated power value reached 0.826. Twenty patients were randomly allocated in a ratio of 1:1 to each group for the RCT.

Primary endpoint and secondary endpoint

Request a detailed protocol

As the study was designed for observing the local tumor control, the primary endpoint was tumor objective response rate to the first treatment, measured by viable tumor residue (VTR), and the secondary endpoint was the overall survival.

Definition of relative therapeutic improvement

Request a detailed protocol

Relative therapeutic improvement by bicarbonate is defined as [(μ1-μ2)/μ1] × (100%), where μ1 is the mean percentage of viable tumor residues after treatment (cTACE) and μ2 the mean percentage of viable tumor residues after treatment (TILA-TACE). The maximum therapeutic improvement is 100%.

Quantitative calculation of viable tumor residues after treatment

Request a detailed protocol

The enhanced area and nonenhanced area in every slice of a tumor (2 mm thichness of each image if scanned by 3.0T MRI Discovery 750, GE Medical Systems or 3.5 mm thichness of each image if scanned by 3.0T MRI Signa Excite HD,GE Medical Systems), which was confirmed by 2 radiologists, was integrated according to MIPAV software (Partecke et al., 2011) (http://mipav.cit.nih.gov/). Summation of integrated enhanced and nonenhanced area of all slices of a tumor gave the viable and necrotic volumes of a tumor. Total tumor volume was the sum of viable and necrotic volume.

Viable tumors were assessed by MRI according to EASL criteria. The enhanced and non-enhanced areas represent viable and necrotic tumors. MRI examinations were performed on a 3.0T MRI (Signa Excite HD,GE Medical Systems,USA) or 3.0T MRI (Discovery 750, GE Medical Systems, USA). We assessed the necrotic and non-necrotic volume using T1 post gadolinium. In some cases, when the T1 post gadolinium image of the lesions did not show typical enhancement, we confirmed these lesions using imaging sequence of DWI and T2W.

The parameters of 3.0T MRI (Signa Excite HD,GE Medical Systems，USA) were as follows: T1WI fast gradient echo sequence TR/TE 180/2.4, FOV 40 × 36 cm, slice thickness 7 mm; T2WI fast spin echo sequence, TR/TE 6000/104.2, FOV 40 × 28 cm, slice thickness 7 mm; DWI single-shot spin-echo echo-planar imaging, SS-SE-EP, b value 600 sec/mm2, TR/TE 1300/52.3, FOV 40 × 40 cm, slice thickness 7 mm; Dynamic contrast-enhanced LAVA sequence, inversion time 5.0 s, TR/TE 2.7/1.3, FOV 40 × 40 cm; slice thickness 4 mm.

The parameters of 3.0T MRI (Discovery 750, GE Medical Systems, USA) were: T1WI fast gradient echo sequence, TR/TE 4.2/1.9, FOV 36 36 cm, slice thickness 4 mm; T2WI fast spin echo sequence, TR/TE 6666/65.3, FOV 36 × 36 cm, slice thickness 5 mm; DWI single-shot spin-echo echo-planar imaging, SS-SE-EP, b value 800 sec/mm2, TR/TE 6000/53.1; FOV 36 × 36 cm, slice thickness 5 mm; Dynamic contrast-enhanced LAVA sequence, inversion time 5.0 s, TR/TE 3.8/1.6, FOV 36 × 36 cm, slice thickness 4 mm.

European association for the study of the liver (EASL) criteria of tumor response to treatment

Request a detailed protocol

The targeted-tumor response to treatment was assessed 30 days after the first treatment according to EASL criteria (Bruix et al., 2001) and defined as below: complete response (CR), no obvious viable residues; partial response (PR), viable residues <50%; stable disease (SD), viable tumor residues between >50% but ≤100%; and progressive disease (PD), viable tumors >100%.

Overall survival

Request a detailed protocol

Overall survival was measured from the date of the first treatment until the date of death or the final follow up visit.

Treatment

Request a detailed protocol

TILA-TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China) that was advanced to celiac artery. The tumor feeding arteries were defined by digital subtraction angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate (5% Sodium Bicarbonate Injection, Hunan Kelun Pharmaceutical, Ltd., Hunan, China) was infused alternatively with doxorubicin-lipiodol emulsion and oxaliplatin/homocamptothecin with the dose adjusted to tumor size . The dose of bicarbonate ranged between 50 and 250 ml corresponding to tumor sizes between 5 and 14 cm. Finally, the artery was permanently embolized with PVA of proper sizes (Embosphere, BioSphere Medical, Paris, France) and microcoil (Tornado, COOK Medical, USA).

The following example may give a clearer description of the procedure:

If a tumor (10 cm) is to be treated, according to our experience, we would prepare 150 ml 5% bicarbonate, 60 ml lipiodol doxorubicin emulsion (40 mg doxorubicin dissolved in 30 ml contrast medium and mixed with 30 ml lipiodol), oxaliplatin 150 mg in 20 ml 5% glucose, 40 mg homocamptothecin in 20 ml saline, PVA particles (100–300, 300–500, 500–700, or 700–900 μm), and microcoil. The TILA-TACE procedure would be as follows

  1. Superselectively identify all tumor feeding arteries.

  2. Estimate roughly the tumor volume covered by each tumor feeding artery. If there are 3 tumor feeding arteries, divide bicarbonate, doxorubicin-lipiodol emulsion, oxaliplatin, homocamptothecin into 3 parts. If they cover nearly the same volume of tumor, then divide the agents into 3 equal parts. If this is the case, the procedures will be as below:

  3. In each tumor feeding artery, about 25 ml bicarbonate would be injected into tumor feeding artery.

  4. Then, 3 ml doxorubicin-lipiodol emulsion, 1 ml oxaliplatin, 1 ml homocamptothecin, 3 ml bicarbonate, 20–40 PVA particles (PVA particle size would be chosen according to the diameter of artery), are sequentially injected.

  5. Repeat step 4 until the tumor supported by this artery is totally filled (lipiodol oil injection was monitored under fluoroscopic guidance). This cycle may repeat several times.

  6. Embolize the tumor feeding artery using PVA of suitable size to block blood stream. Microcoil is used to prevent washout of lipiodol by blood stream, if the diameter of the tumor feeding artery is large, e.g., the internal diameter is larger than 2 mm.

  7. The fully occlusion of feeding artery is confirmed by DSA angiography. The deposit of lipiodol oil was assessed by C-arm CT.

  8. Repeat step 3 to 7 on the second and the third feeding artery.

cTACE was performed the same as above, except no bicarbonate.

Retreatment was based on the evidence of viable tumor residues. The average sessions of treatment were 4 (range 1–13).

Adverse events

Request a detailed protocol

The following adverse events which might occur during and after TACE procedure were monitored: blood pressure and oxygen saturation during TACE, pain, fever, and signs of liver decompensation after treatment, and biliary system.

Statistical analysis

Request a detailed protocol

Differences in viable tumor residues after the first treatment (the primary endpoint of the study) between the two treatment groups cTACE and TILA-TACE were examined using unpaired t-tests and were further adjusted for viable tumor volume before treatment and other potential confounding factors using the general linear model. Log-transformation was conducted to normalize the distribution of viable tumor residues and viable tumor volume before treatment in parametric analyses, with assigning 1 to viable tumor residues if the measured value (ranging 0–216.5%) was 0. We also categorized tumor responses to treatment into four categories according to EASL criteria. Differences in the distribution of categories of tumor responses to treatment between two treatment groups were examined using the proportional odds model after adjustment for viable tumor volume before treatment. Overall survival time was calculated from the date of the first treatment to the date of death from any cause or the last follow-up visit (October 31, 2015). Distributions of overall survival were charted by Kaplan-Meier method and compared with the log-rank test. The overall survival in the RCT was assessed using both the intent-to-treat and per-protocol methods. A two-sided alpha of 0.05 was used for all tests.

References

    1. Schwickert G
    2. Walenta S
    3. Sundfør K
    4. Rofstad EK
    5. Mueller-Klieser W
    (1995)
    Correlation of high lactate levels in human cervical cancer with incidence of metastasis
    Cancer Research 55:4757–4759.
    1. Walenta S
    2. Salameh A
    3. Lyng H
    4. Evensen JF
    5. Mitze M
    6. Rofstad EK
    7. Mueller-Klieser W
    (1997)
    Correlation of high lactate levels in head and neck tumors with incidence of metastasis
    The American Journal of Pathology 150:409–415.
    1. Walenta S
    2. Wetterling M
    3. Lehrke M
    4. Schwickert G
    5. Sundfør K
    6. Rofstad EK
    7. Mueller-Klieser W
    (2000)
    High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers
    Cancer Research 60:916–921.

Decision letter

  1. Chi Van Dang
    Reviewing Editor; University of Pennsylvania, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article "Intratumoral lactic acidosis is a promising therapeutic target for cancer therapy" for consideration by eLife. Your article has been favorably evaluated by Charles Sawyers as the Senior editor and four reviewers, including Robert Gatenby and Chi Dang, who is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors report that local bicarbonate infusion prior to transarterial chemoembolization (TACE) of large hepatocellular carcinomas (HCCs) resulted in remarkable improvement in tumor responses in a nonrandomized cohort of 57 patients followed by a randomized control 20 patients, which supported the findings of the nonrandomized study. Specifically, the clinical responses with bicarbonate were remarkable with early signs of improved survival for patients with large HCCs. The authors speculated that reducing or "targeting" intra-tumoral lactic acidosis may improve the clinical outcome and reported an objective response rate of 100% in the therapy group vs. 44% in the control group. The authors conclude that bicarbonate local infusion markedly enhances the anticancer activity of TACE. If validated, this approach could be a significant improvement over current TACE and support the notion that cancer metabolism, and in this case – acidity, could be manipulated in the clinic. While the data are of significant interest, there are some major concerns that must be addressed.

Essential revisions:

1) The authors should provide additional details on the clinical protocol for administration of bicarbonate and subsequent chemoembolization so that others could reproduce the study. It is not clear whether and how the area and timing of the "local bicarbonate" injection and TACE overlaps to account for the therapeutic advantages. Since both local bicarbonate injection and TACE are both local treatments, how these two local treatments are related to each other are critical information that are missing from this manuscript.

2) In the TACE group, were the patients treated with a placebo, such as saline injection to control for the placebo or procedure-related events that contribute to the differences in outcomes?

3) The control arm with TACE alone achieved a survival of only 14 months, which is far below the expected survival outcomes available in the literature and various treatment guidelines. This may be due to the fact that both BCLC B and C patients were enrolled, which by itself is adding confusion to the interpretation of the data.

4) The authors report a 100% response rate using EASL. If this was the case, the expected survival should really be much greater in the experimental arm. The authors do not make any comments on this fact. In addition, they do not report whether the tumors recurred or whether the patients had to be re-treated. These are critically important clinical questions that the authors must address. The sample sizes appear small to reach confident conclusions. Additional supplemental data files on the individual patients would add significantly and document the data in more detail. The statistical analysis needs much more details in terms of the local control benefit and how to correct for the patients' cross-over between the two treatment groups.

5) Given the complexity of the sample recruitment and group changing during the trial, CONSORT Flow Diagram and checklist will be important and helpful to make the data more transparent and interpretable.

https://doi.org/10.7554/eLife.15691.sa1

Author response

Essential revisions:

1) The authors should provide additional details on the clinical protocol for administration of bicarbonate and subsequent chemoembolization so that others could reproduce the study. It is not clear whether and how the area and timing of the "local bicarbonate" injection and TACE overlaps to account for the therapeutic advantages. Since both local bicarbonate injection and TACE are both local treatments, how these two local treatments are related to each other are critical information that are missing from this manuscript.

We added a detailed protocol of TILA-TACE in the Methods section:

“The following example may give a clearer description of the procedure:

If a tumor (10 cm) is to be treated, according to our experience, we would prepare 150 ml 5% bicarbonate, 60 ml lipiodol doxorubicin emulsion (40 mg doxorubicin dissolved in 30 ml contrast medium and mixed with 30 ml lipiodol), oxaliplatin 150 mg in 20 ml 5% glucose, 40 mg homocamptothecin in 20 ml saline, PVA particles (100-300, 300-500, or 500-700,700-900 μm), and microcoil.

[…]

8. Repeat step 3 to 7 on the second and the third tumor feeding artery.”

2) In the TACE group, were the patients treated with a placebo, such as saline injection to control for the placebo or procedure-related events that contribute to the differences in outcomes?

We agree with the reviewers’ comment that the control group should have been treated with placebo (saline), but in this case, we did not use saline as placebo, because saline injection will change our standard cTACE protocol that we performed for years. If we add saline into the procedure, then the comparison would not be between TILA-TACE and standard cTACE.

In addition to the mechanism by which bicarbonate enhances the anticancer activity of TACE described in our manuscript, there is another mechanism that bicarbonate could enhance the anticancer activity of TACE. As the weakly basic doxorubicin is more toxic in basic pH than in acidic pH condition, intratumoral alkalization by bicarbonate would potentiate the cytotoxicity of doxorubicin. This is a critical point that should be clarified. Therefore, we initiated another small randomized controlled study (Title: Randomized controlled study of bicarbonate-enhanced transarterial chemoembolization and transarterial embolization in treatment of hepatocellular carcinoma; registration number ChiCTR-IPR-15006025 in Chinese Clinical Trial Registry), in which, patients were randomly assigned to TILA-TACE or TILA-TAE (transarterial embolization, the same as TILA-TACE, except no chemotherapeutic agents). So far, 36 patients have been treated, and the objective tumor response rates between TILA-TACE and TILA-TAE group were virtually the same. The study is ongoing, but the results achieved so far strongly suggest that bicarbonate is the major agent that results in massive death of HCC, because chemotherapeutic agents (with or without) did not make a significant difference (100% objective response rate (ORR) of the targeted tumors in the TILA-TACE arm versus 93% ORR of the targeted tumors in the TILA-TAE arm).

Although the above evidence cannot directly answer the question as to whether the same amount of saline injection would exert a similar effect to bicarbonate, it demonstrated that local bicarbonate injection into HCC is effective in control of the tumor.

3) The control arm with TACE alone achieved a survival of only 14 months, which is far below the expected survival outcomes available in the literature and various treatment guidelines. This may be due to the fact that both BCLC B and C patients were enrolled, which by itself is adding confusion to the interpretation of the data.

The control arm with cTACE treatment achieved a median survival of 14 months. At the first glance, the median survival seems short. However, after close analysis, this median survival is most probably not below the expected survival outcome, if the patients’ disease characteristics, particularly BCLC staging and tumor size, are taken into consideration. In this control arm, 27 HCC patients included 9 BCLC C and 18 BCLC B, among which there were 15 patients with tumor size larger than 10 cm and 3 patients with tumor size close to 10 cm (9.4, 9.1, and 8.6 cm). We did not find a paper that reported survival of patients with disease characteristics comparable to the patients in our study, but we may take the reported survival data of patients with different tumor stages and tumor size as references, as detailed below:

Overall survival wise, TACE is more effective for patients with less tumor burden and higher liver reserve than those with higher tumor burden and lower liver reserve (Sieghart et al., 2015; Llovet et al., 2002; Lo et al., 2002; Malagari et al., 2012; Burrel et al., 2012; Takayasu et al., 2012) e.g., the 3-year survival rates for ideal TACE candidates (low tumor burden at BCLC stage A or BCLC stage B) could reach 55%-65% (Malagari et al, 2012; Burrel et al., 2012; Takayasu et al., 2012) whereas the 3-year survival rates for less rigorously selected patients were only 26 – 29% (Llovet et al., 2002; Lo et al., 2002). The 3 year survival of the control arm in this current study was 25.9%.

Tumor size appears to be a major factor to affect survival. LIovet et al. (2002) reported a 30 months median survival of patients at BCLC B and C with tumor size between 4.0 – 5.8 cm; Lo et al. (2002) reported a 17 months median survival of patients at BCLC B and C with tumor size between 4.0 – 14 cm; Huang et al. (2006) Jing-Huan Li (2015), and Paul et al. (2011) reported 9-10 months median survival of patients at BCLC B and C with tumor size larger than 10 cm.

For HCC patients at BCLC C stage, the recommended treatment is sorafenib. Current situation for patients with advanced HCC is desperate. Sorafenib is recommended for treating patients of BCLC C category. Two landmark studies confirmed that sorafenib could prolong modestly the median survival of patients in comparison to placebo (Cheng et al., 2009; Llovet et al., 2008). Cheng et al. reported a median survival of 6.5 months (sorafenib arm) versus 4.2 (placebo), and LIovet et al. reported a median survival of 10.7 months (sorafenib arm) and 7.9 months (placebo). The median survival of 10.7 months in the sorafenib arm was reproduced by several studies (Cheng et al., 2013; Cainap et al., 2015; Johnson et al., 2013).

If the references listed above and the disease characteristics of the patients in our study were taken into consideration, the median survival time of the patients in the control arm of the current study may be not worse than the reported ones.

References:

1) Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319): 1734-9.

2) Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35(5): 1164-71.

3) Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; 35(5): 1119-28.

4) Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56(6): 1330-5.

5) Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012; 56(4): 886-92.

6) Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Alimentary pharmacology & therapeutics. 2006; 23(1): 129-35.

7) Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World journal of gastroenterology. 2015; 21(13): 3970-7.

8) Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, et al. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. The Indian journal of radiology & imaging. 2011; 21(2): 113-20.

9) Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25-34.

10) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378-90.

11) Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(32): 4067-75.

12) Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33(2): 172-9.

13) Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(28): 3517-24.

4) The authors report a 100% response rate using EASL. If this was the case, the expected survival should really be much greater in the experimental arm. The authors do not make any comments on this fact.

The 100% ORR in the TILA-TACE group includes CR and PR of the targeted tumors. Many previous studies have confirmed that better local control was an independent prognostic indicator for patient survival (Kim et al., 2015; Shim et al., 2012; Jung et al., 2013; Kim et al., 2013; Riaz et al., 2011; Gillmore et al., 2011; Riaz et al., 2010), and Kim et al. (2015) and Shim et al (2012) further demonstrated that there was a clear prognostic difference between CR, PR, SD, and PD and that PR patients showed a significantly poorer survival than CR patients. Moreover, in the follow up, 16 patients eventually exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis, all of which accounted for the death in the experimental arm (Supplementary file 2). These observations also suggest that fast CR and timely control of recurrent tumors in the liver would likely improve the survival of patients, especially those with large tumor burden and low liver reserve. We also mentioned it in the Discussion section of the revised manuscript (third paragraph).

In addition, they do not report whether the tumors recurred or whether the patients had to be re-treated. These are critically important clinical questions that the authors must address.

In the follow up, 16 patients ultimately exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis. We added the information into the revised manuscript (Discussion section, third paragraph, and Supplementary files 1–3).

In the Methods section, we added “Retreatment was based on the evidence of viable tumor residues. The average sessions of treatment were 4 (range 1-13)”.

The sample sizes appear small to reach confident conclusions. Additional supplemental data files on the individual patients would add significantly and document the data in more detail.

We added Supplementary files 1–3, which provide detailed information of the patients.

The statistical analysis needs much more details in terms of the local control benefit and how to correct for the patients' cross-over between the two treatment groups.

In the non-randomized cohort of the study, patients recruited in the treatment and control groups differed in some clinicopathological characteristics, although the same inclusion/exclusion criteria were used. In the revised manuscript, we evaluated whether treatment effects (assessed by viable tumor residues, VTR) were confounded by these clinical parameters such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, viable tumor volume before treatment, macrovascular invasion, and tumor multifocality using general linear models. Among them, only viable tumor volume before treatment was significantly associated with VTR. We also found a similar association for macrovascular invasion, being of statistically borderline significance. Therefore, we adjusted for these two covariates and estimated multivariable-adjusted VTR using the general linear model. We found that adjustment for these potential confounding factors did not materially alter the results, suggesting that the finding of remarkable improvement in tumor responses in the TILA-TACE vs. cTACE was independent of patients’ clinicopathological characteristics.

We also used the proportional odds model to adjust for viable tumor volume before treatment when comparing differences in the distribution of categories of tumor responses to treatment between two treatment groups.

The overall survival in the RCT was assessed using both the intent-to-treat (ITT) and per-protocal (PP) methods. There was no apparent difference in overall survival between two treatment groups in the ITT analysis. However, a survival advantage appears in TILA-TACE treatment over cTACE treatment in the PP analysis. PP analyses may provide a better sense of the actual biological effect of treatment but are like to introduce biases to the study because of abolishment of randomization. We acknowledged these limitations of the present small RCT in the revised manuscript. We are planning a large-scale RCT to further examine both targeted/local tumor responses, overall and progression-free survival with bicarbonate TACE in patients with large HCCs.

We added the information into in the revised manuscript (Methods, subsection “Statistical analysis”, and Results section).

5) Given the complexity of the sample recruitment and group changing during the trial, CONSORT Flow Diagram and checklist will be important and helpful to make the data more transparent and interpretable.

We added a CONSORT Flow Diagram (Reporting standard 1) and a CONSORT-checklist (Reporting standard 2).

https://doi.org/10.7554/eLife.15691.sa2

Article and author information

Author details

  1. Ming Chao

    Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Conceived the conception, Designed the study, Performed TACE, Wrote the paper, Critical revision, Analysis and interpretation of data, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  2. Hao Wu

    Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Conceived the conception, Designed the study, Analyzed the data, Wrote the paper, Critical revision, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  3. Kai Jin

    Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Performed TACE, Analyzed the data, Critical revision, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  4. Bin Li

    Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Performed TACE, Analysis and interpretation of data, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  5. Jianjun Wu

    Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Performed TACE, Analysis and interpretation of data, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  6. Guangqiang Zhang

    Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Performed TACE, Analysis and interpretation of data, Contributed unpublished essential data or reagents
    Competing interests
    No competing interests declared

  7. Gong Yang

    Vanderbilt University Medical Center, Nashville, United States
    Contribution
    Critical revision, Analyzed the data
    Competing interests
    No competing interests declared

  8. Xun Hu

    Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
    Contribution
    Conceived the conception, Designed the study, Wrote the paper, Analyzed the data, Critical revision, Contributed unpublished essential data or reagents
    For correspondence
    huxun@zju.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3784-371X

Funding

National Natural Science Foundation of China (81301707)

  • Hao Wu

China National 973 Project (2013CB911303)

  • Xun Hu

National Natural Science Foundation of China (81272456)

  • Xun Hu

Ministry of Education of the People's Republic of China (Fundamental Research Funds for the Central Universities)

  • Xun Hu

National Natural Science Foundation of China (81470126)

  • Xun Hu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This work has been supported in part by the China National 973 project (2013CB911303), China Natural Sciences Foundation projects (81272456, 81470126, 81301707) and the Fundamental Research Funds for the Central Universities, National Ministry of Education, China. The funders have no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. We thank professors Guo-Hua Fong (University of Connecticut School of Medicine), Mingliang He (The Chinese University of Hong Kong), for critical reading of this manuscript and constructive comments.

Ethics

Clinical trial registration registration number: ChiCTR-IOR-14005319 in Chinense Clinical Trial Registry; protocol can be assessed at http://www.medresman.org/; available as Supplementary file 5).

Human subjects: The study was performed with patients' written informed consent and with the approval of hospital's Institutional Review Board (The Second Affiliated Hospital, Zhejiang University School of Medicine).

Reviewing Editor

  1. Chi Van Dang, University of Pennsylvania, United States

Version history

  1. Received: March 2, 2016
  2. Accepted: June 30, 2016
  3. Version of Record published: August 2, 2016 (version 1)
  4. Version of Record updated: February 19, 2020 (version 2)
  5. Version of Record updated: April 1, 2020 (version 3)

Copyright

© 2016, Chao et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 18,496
    Page views
  • 2,357
    Downloads
  • 51
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ming Chao
  2. Hao Wu
  3. Kai Jin
  4. Bin Li
  5. Jianjun Wu
  6. Guangqiang Zhang
  7. Gong Yang
  8. Xun Hu
(2016)
A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
eLife 5:e15691.
https://doi.org/10.7554/eLife.15691

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1

    Huan Fang, Wenlong Ren ... Ceshi Chen
    Research Article

    Anti-tumor drug resistance is a challenge for human triple-negative breast cancer (TNBC) treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote TNBC cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin β4. Integrin β4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in TNBC. These results indicate that the Integrin β4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in TNBC.

    1. Cancer Biology

    ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

    Elena Farmaki, Aritro Nath ... Andrea H Bild
    Research Article

    The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, sensitive or resistant to everolimus, and discovered that combination treatment of ONC201/TIC10 with everolimus inhibited cell growth in 2D/3D in vitro studies. We confirmed increased therapeutic response in primary patient cells progressing on everolimus, supporting clinical relevance. We show that ONC201/TIC10 mechanism in metastatic ER+ BC cells involves oxidative phosphorylation inhibition and stress response activation. Transcriptomic analysis in everolimus resistant breast patient tumors and mitochondrial functional assays in resistant cell lines demonstrated increased mitochondrial respiration dependency, contributing to ONC201/TIC10 sensitivity. We propose that ONC201/TIC10 and modulation of mitochondrial function may provide an effective add-on therapy strategy for patients with metastatic ER+ BCs resistant to mTOR inhibitors.

    1. Cancer Biology
    2. Computational and Systems Biology

    High-content microscopy reveals a morphological signature of bortezomib resistance

    Megan E Kelley, Adi Y Berman ... Gregory P Way
    Research Article

    Drug resistance is a challenge in anticancer therapy. In many cases, cancers can be resistant to the drug prior to exposure, i.e., possess intrinsic drug resistance. However, we lack target-independent methods to anticipate resistance in cancer cell lines or characterize intrinsic drug resistance without a priori knowledge of its cause. We hypothesized that cell morphology could provide an unbiased readout of drug resistance. To test this hypothesis, we used HCT116 cells, a mismatch repair-deficient cancer cell line, to isolate clones that were resistant or sensitive to bortezomib, a well-characterized proteasome inhibitor and anticancer drug to which many cancer cells possess intrinsic resistance. We then expanded these clones and measured high-dimensional single-cell morphology profiles using Cell Painting, a high-content microscopy assay. Our imaging- and computation-based profiling pipeline identified morphological features that differed between resistant and sensitive cells. We used these features to generate a morphological signature of bortezomib resistance. We then employed this morphological signature to analyze a set of HCT116 clones (five resistant and five sensitive) that had not been included in the signature training dataset, and correctly predicted sensitivity to bortezomib in seven cases, in the absence of drug treatment. This signature predicted bortezomib resistance better than resistance to other drugs targeting the ubiquitin-proteasome system. Our results establish a proof-of-concept framework for the unbiased analysis of drug resistance using high-content microscopy of cancer cells, in the absence of drug treatment.